Highlights

  • Third-quarter 2026 reported sales rose 6% to US$1.02 billion, with core sales up 5% from a year earlier.
  • Deconsolidating the Russian Subsidiary cut diluted EPS by US$0.94, leaving reported Earnings at US$0.51 per share.
  • Adjusted EPS of US$1.52 landed at the high end of guidance, compared with US$1.62 a year earlier.
  • The board raised the quarterly Dividend to US$0.50 per share, payable on 3 December 2026.

AptarGroup, Inc. (NYSE:ATR) posted higher third-quarter sales on 29 October 2026, as growth in its Beauty and Closures businesses offset softer emergency medicine Demand in Pharma, while a one-off loss on its Russian operations sharply reduced reported earnings.

The dispensing and packaging solutions maker deconsolidated its Russian subsidiary after a government decree placed the Business under external administration, ending Aptar's control.

Sales Growth Led by Beauty and Closures

Reported sales for the three months ended 30 September 2026 rose 6% to US$1.02 billion, and core sales grew 5%. Closures led the way with reported and core growth of 11%, supported by beverage and food demand including bottled water, concentrates and condiments. Beauty sales rose 9%, or 8% on a core basis, on demand for prestige fragrance, color cosmetics and hair care, along with pass-through of higher input costs.

Pharma reported sales grew 2% and core sales 1%, as gains in central nervous system and pulmonary applications were partly offset by emergency medicine destocking. Excluding emergency medicine, Pharma core sales rose 8%, and the segment's adjusted EBITDA Margin of 36.4% stayed above its long-term target.

Russia Loss Weighs on Reported Earnings

The Russian deconsolidation produced a US$58.0 million loss, including about US$30.0 million of cash held by the subsidiary, for a total after-tax impact of US$60.4 million, or US$0.94 per diluted share. Net Income fell to US$32.8 million and reported diluted EPS to US$0.51 from US$1.92.

Adjusted EPS, a non-GAAP measure, was US$1.52 versus US$1.62 a year earlier at comparable exchange rates. Adjusted EBITDA reached US$217.2 million, but the margin narrowed to 21.3% from 23.2%, with all three segments recording lower margins. Free Cash Flow for the quarter was US$98.6 million.

Higher Dividend and Continued Buybacks

Aptar repurchased about 234,000 shares for US$30 million in the quarter and returned US$272 million to shareholders year to date through Buybacks and dividends. After quarter-end, the board approved a quarterly dividend of US$0.50 per share, up from US$0.48, payable on 3 December 2026 to shareholders of record on 12 November 2026.

Fourth-Quarter Guidance and New Leadership Priorities

For the fourth quarter of 2026, management expects adjusted EPS of US$1.39 to US$1.47, compared with US$1.22 a year earlier, based on an effective tax rate of 17.5% to 19.5% and a euro to US dollar rate of 1.12. It anticipates about US$4.0 million of pre-tax restructuring adjustments.

Management expects a strong finish to 2026, led by Pharma growth in consumer healthcare and injectables, continued Closures momentum and a focus on improving North American Beauty operations. President and Chief Executive Officer Gael Touya, at the start of his tenure, set four priorities: deepening customer relationships, accelerating innovation, executing more consistently and allocating Capital thoughtfully. Shares closed at US$137.20 on 30 October 2026, up 5.02% on the day, giving a market Capitalization of about US$8.72 billion.